Issue link: http://osercommunicationsgroup.uberflip.com/i/709458
C h a i n D r u g s t o r e D a i l y Tu e s d a y, A u g u s t 9 , 2 0 1 6 2 6 FIVE TRENDS IN CREDIT CARD FRAUD By Jeff Ditges, President, Source Communications The switch to EMV last year has resulted in more secure credit card processing, and in card present transactions, fraud decreased in 2015. However, fraudsters continue to expand their efforts in an ever increasing variety of fraud schemes. Here are the top five trends in credit card fraud from 2015, as cited in the LexisNexis ® Risk Solutions True Cost of Fraud SM Study. 1. A Rise in Debit Card Fraud Fraudsters made use of as much breached and skimmed card data as possible last year by enacting more debit card fraud. Merchants who accept debit cards attrib- uted 30 percent of fraud to this type of payment. Though with the advent of EMV, it was expected, the debit card fraud numbers surged in 2015. 2. Card Skimming is Moving to Small Merchants With larger merchants moving to EMV system, fraudsters are seeking out small- er merchants who have not yet converted to the chip and pin technology. Some small merchants saw as much as double the number of card skimming fraud attacks in 2015. One way to prevent these attacks is with secure card stands. 3. More Fraud Online Not surprisingly, as mer- chants reterminalize for EMV, fraudsters are mov- ing their tactics online. Purchases that don't require a card to be inserted or swiped at all are fraudster's favorite kinds of transactions. In fact, more than half (55 percent) of all fraud experienced by merchants was from online payment fraud, which rose a staggering 31 percent in 2015. 4. In-Store Pickups Produce Considerable Shrink Brick and mortar merchants are making use of their omnichannel presence to give consumers the convenience of in-store pickups. However, these transactions made up 25 percent of lost and stolen merchandise (shrink) in 2015 among all major merchant segments. 5. Increase in the Average Monthly Volume of Fraudulent Transactions In 2014, merchants had an average of 298 fraudulent transactions each month. That number surged to 333 transactions in 2015. However, the number of fraud attacks they were able to prevent in that same time also increased 12 percent. Your credit card readers are only as secure as the stands that they rest on. Visit Source Communications to learn more about securing your card readers. Visit Source Communications at booth #1467. SUN PHARMA CONTINUES EXPANDING PRODUCT PORTFOLIO The world's largest pharmaceuticals mar- ket is also the biggest market for Sun Pharma. It has been present in the U.S. since 1996, working with the country's healthcare system with a focus on gener- ics, branded generics and over-the-count- er (OTC) products. It is a valued supplier to the largest wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers. Being a vertically integrated company with a global presence, Sun Pharma has the flexibility to develop and manufac- ture products in the U.S. as well as at other locations across the world. Its U.S. headquarters are in Cranbury, New Jersey and it has distribution and cus- tomer service teams at multiple locations across the country. Sun Pharma is present in the U.S. through its own legal entities as well as its subsidiary, Taro Pharmaceuticals. Sun Pharma has made several acquisitions in the U.S., including Caraco, DUSA Pharmaceuticals and Pharmalucence. Currently, it is a market leader in the generic dermatology sector, with a broad product portfolio for the treatment of actinic keratosis, fungal infections and acne. It has strong capabilities in devel- oping complex products and has a robust pipeline of ANDAs, including high value First-to-File (FTF) opportunities. Sun Pharma's latest acquisition of a majority interest in Ranbaxy Laboratories Limited (Ranbaxy) and its Ohm Laboratories facilities in the New Jersey makes it the largest Indian pharma company in the U.S. market, with a sig- nificantly expanded portfolio of life-sav- ing and enhancing medicines. Sun Pharma and Ranbaxy have similar back- grounds and corporate values, with cus- tomer-oriented cultures and research- driven business models. Ranbaxy fits in well with Sun Pharma's network of com- panies serving the U.S. healthcare sys- tem. Taro markets a broad range of pre- scription and OTC products. It is a lead- ing manufacturer and supplier of topical dermatologicals, with a growing line of both topical products and solid dosage formulations mainly used in cardiology and neurology therapies. DUSA is focused on the development and marketing of dermatology products. DUSA's flagship product, Levulan ® pho- todynamic therapy (PDT), is a technology platform used in con- junction with its proprietary light source, the BLU-U ® Blue Light Photodynamic Therapy Illuminator, for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. Pharmalucence is a manufacturer of non-cytotoxic human injectable pharma- ceuticals, in either liquid or lyophilized form. It also specializes in radio pharma- ceutical products. Pharmalucence's 70,000 square foot manufacturing facili- ty is the region's first unit to utilize fully automated and isolated aseptic technolo- gy in support of a wide array of needs, from small clinical fills up to full com- mercial scale production for markets worldwide. Ohm Laboratories is a manufacturer of prescription and OTC drugs in solid dosage forms. Ohm is also approved to manufacture controlled substances by the U.S. Drug Enforcement Agency (DEA). Its state-of-the-art laboratory, manufacturing and warehousing facili- ties are capable of handling high-volume products and large batch sizes, while its supply chain efficiency ensures seam- less transportation to customer locations. Ohm is a frontrunner in bringing unique product deliveries and complex combi- nations to the market. Sun Pharma has built a strong repu- tation as a company that is market driven, focused on customer service and capable of offering a wide range of affordable pharmaceutical products. It continues to expand its product portfolio in the U.S. market to the benefit of patients, pre- scribers and other stakeholders in the healthcare system. It provides high-quality, affordable medicines trusted by healthcare profes- sionals and patients in more than 150 countries of the world. Its presence in 65 key markets around the world is sup- ported by 45 manufacturing facilities across five continents. It has a multi- cultural workforce, comprising more than 30,000 employees of more than 50 nationalities. Visit Sun Pharma at booth #1409. For more information, call 914.345.9001 or go to www.sunpharma.com.